Business Wire

PA-BOOMI

13.6.2022 15:22:08 CEST | Business Wire | Press release

Share
Boomi Appoints New Leaders To Support Rapid Customer Growth After Successful Spin Off As A Newly Independent Company

Boomi™ , the intelligent connectivity and automation leader, today announced the appointment of Madeline Ling as chief financial officer (CFO), Marcy Campbell as chief revenue officer (CRO), and Fran Wilson as chief marketing officer (CMO), effective immediately. Additionally, Emmy award-winning news journalist Christa Delcamp joins Boomi to support public relations and media strategy, and James Dyson joins the company to lead Global Diversity, Equity, and Inclusion Talent Acquisition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005227/en/

“Boomi's recent launch as a standalone company – coupled with our high growth and cutting-edge, cloud-based technology – provides the opportunity to build our leadership team as part of a much larger expansion, with several hundred new hires coming onboard this year,” said David Meredith, CEO at Boomi. “Our industry-leading platform and award-winning culture enabled us to recruit top, globally-minded talent, with a demonstrated track-record of achievement, and a passion to accelerate our mission to make the world a better place by connecting everyone to everything, anywhere.”

The new leadership appointments come after Boomi's recent independence backed by premier private equity firms, Francisco Partners and TPG, in a $4 billion transaction. As a global software as a service (SaaS) category leader with more than 20,000 customers – Boomi touts a growing user community of over 100,000 members , a worldwide network of more than 800 partners , and one of the largest arrays of global system integrators (GSI) in the iPaaS space, which includes Accenture, Deloitte, SAP, and Snowflake, as well as the three largest cloud providers, Amazon Web Services, Google, and Microsoft, among others.

Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for enterprise platform as a service (EiPaaS)1 for eight consecutive years . The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces . As the company continues to scale rapidly to meet global, enterprise demand for digital connectivity, integration, and automation, Boomi plans to hire several hundred new team members this year to accelerate all functions of the business.

BOOMI ATTRACTS WORLD-CLASS TALENT:

Madeline Ling, CFO
Ling holds a MBA from Stanford Graduate School of Business, and brings nearly 25 years of experience leading equity-backed, global enterprise organizations through strategic and international growth. She has held multiple CFO roles throughout her career, including international assignments overseas. Ling most recently served as corporate CFO for a Hellman and Friedman (H&F) PE-backed portfolio company, and held previous roles at VMware, The Boston Consulting Group, and Intel.

Marcy Campbell, CRO
Campbell brings to Boomi over 30 years of experience leading large-scale, go-to-market organizations for global companies ranging from Fortune 500 to venture-backed technology firms. She most recently served as senior vice president at PayPal where she led global sales, professional services, and operations. At Boomi, Campbell will spearhead the company’s revenue-generating strategies with a focus on driving fast growth, while continuing to deliver customer value.

Fran Wilson, CMO
With more than 20 years of successful experience in SaaS and B2B enterprise software organizations, Wilson provided marketing leadership through Red Hat’s initial public offering (IPO), and during its rapid revenue growth from $400 million to more than $4 billion, culminating in its sale to IBM for $34 billion.

Christa Delcamp, Public Relations and Media Strategy
Delcamp brings over two decades of experience in public relations, journalism, content creation, and communications, across a variety of platforms, including digital/social, NBC and CBS-owned and operated stations, radio/podcasting, and print. An Emmy award-winning news journalist, Delcamp’s extensive expertise in telling impactful stories will help Boomi increase market awareness of its industry-leading platform and important mission to connect the world.

James Dyson, Global Diversity, Equity, and Inclusion (DE&I) Talent Acquisition
Dyson brings over 20 years of experience leading and managing talent acquisition at global companies, including Accenture. In his role, Dyson will leverage his deep expertise and extensive international network to support Boomi’s rapid growth and continue to build the company’s award-winning culture.

Additional Resources

Gartner Disclaimer:

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.

About Boomi

Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com .

© 2022 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

________________________
1 Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021

Link:

ClickThru

Social Media:

https://www.facebook.com/Boomi.Official

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye